Potential for antioxidant therapy of cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 6, 2004, Pages 531-536

  Cantin, André M ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Cystic fibrosis transmembrane conductance regulator; Glutathione; Inflammation; Mucus; Oxidants

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; ALPHA TOCOPHERYLQUINONE; ANTIOXIDANT; ASCORBIC ACID; CALNEXIN; CALRETICULIN; CHLORIDE; CHLORIDE CHANNEL; CURCUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; GLUTATHIONE DERIVATIVE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUCIN; NACYSTELYN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; S NITROSOGLUTATHIONE; SELENOCYSTINE; TAURINE; THIOCTIC ACID; THIOREDOXIN; TOLL LIKE RECEPTOR 4; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

CYSTIC FIBROSIS; DIET; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; LUNG INFECTION; MUCUS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 7444252099     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000138997.29276.a1     Document Type: Review

References (42)

1. Kerem B, Rommens JM, Buchanan JA, et al.: Identification of the cystic fibrosis gene: Genetic analysis. Science 1989, 245:1073-1080.
2. Donaldson SH, Boucher RC: Update on pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med 2003, 9:486-491.
3. Matsui H, Grubb BR, Tarran R, et al.: Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1005-1015.
4. Mall M, Grubb BR, Harkema JR, et al.: Increased airway epithelial Na(+) absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493. Cystic fibrosis transmembrane conductance regulator directly regulates transepithelial anion transport and indirectly controls sodium absorption. CFTR deficiency leads to excessive sodium absorption. This study is the first to indicate that excessive sodium absorption from the airways is sufficient to create a phenotype that is entirely consistent with the airway disease observed in patients with cystic fibrosis.
5. Linsdell P, Hanrahan JW: Glutathione permeability of CFTR. Am J Physiol 1998, 275:C323-C326.
6. Kogan I, Ramjeesingh M, Li C, et al.: CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 2003, 22:1981-1989. Although it had been known for some time that CFTR facilitates glutathione transepithelial flux, it was unknown whether CFTR could directly transport glutathione. Direct evidence of CFTR-mediated glutathione transport lends further support for the hypothesis that a significant function of CFTR is probably related to the regulation of transepithelial redox status. This regulated glutathione transport in cystic fibrosis is directly relevant to the basic defect of CFTR function.
7. Jungas T, Motta I, Duffieux F, et al.: Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator. J Biol Chem 2002, 277:27912-27918. Expression of wild type or mutant CFTR is shown to directly impact not only on extra-cellular redox status but also on cellular responses to oxidant stress. CFTR deficiency increases epithelial cell resistance to oxidant-mediated apoptosis.
8. Roum JH, Buhl R, McElvaney NG, et al.: Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993, 75:2419-2424.
9. Day BJ, van Heeckeren AM, Min E, Velsor LW: Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 2004, 72:2045-2051. This work is important since it not only demonstrates that airway infection induces glutathione secretion but also that this response is absent in airways expressing deficient CFTR. The role of airway glutathione in host defense remains to be elucidated.
10. Arsalane K, Dubois CM, Muanza T, et al.: Transforming growth factor-beta1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the GSH rate-limiting enzyme gamma-glutamyl-cysteine synthetase. Am J Respir Cell Mol Biol 1997, 17:599-607.
11. Cantin AM, Paquette B, Richter M, Larivee P: Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med 2000, 162:1539-1546.
12. Wu L, Ashraf MH, Facci M, et al.: Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci USA 2004, 101:7094-7099.
13. Middleton N, Jelen P, Bell G: Whole blood and mononuclear cell glutathione response to dietary whey protein supplementation in sedentary and trained male human subjects. Int J Food Sci Nutr 2004, 55:131-141.
14. Packer L, Witt EH, Tritschler HJ: alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995, 19:227-250.
15. Howatt WF, DeMuth GR: A double-blind study of the use of acetylcysteine in patients with cystic fibrosis. Univ Mich Med Cent J 1966, 32:82-85.
16. App EM, Baran D, Dab I, et al.: Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J 2002, 19:294-302.
17. Antonicelli F, Parmentier M, Drost EM, et al.: Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med 2002, 32:492-502.
18. Roum JH, Borok Z, McElvaney NG, et al.: Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 1999, 87:438-443.
19. Venglarik CJ, Giron-Calle J, Wigley AF, et al.: Hypochlorous acid alters bronchial epithelial cell membrane properties and prevention by extracellular glutathione. J Appl Physiol 2003, 95:2444-2452.
20. Griese M, Ramakers J, Krasselt A, et al.: Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am J Respir Crit Care Med 2004, 169:822-828. Ever since a deficiency in airway surface liquid glutathione content has been linked to CFTR deficiency, there has been great interest to explore whether correction of the glutathione deficiency can be achieved by glutathione aerosol therapy. This work suggests that the answer is yes, at least transiently. However, glutathione aerosol therapy did not correct the signs of oxidative alterations of airway proteins and lipids. Approaches other than glutathione aerosol therapy may be needed to effectively reestablish the normal redox state of airway surface liquid in the CF lung.
21. Rancourt RC, Tai S, King M, et al.: Thioredoxin liquefies and decreases the viscoelasticity of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2004, 286:L931-L938. This represents a highly novel approach to liquefy CF airway mucus. This approach seems much more effective than other thiols and the glutathione system in creating a mucolytic effect.
22. Zsembery A, Boyce AT, Liang L, et al.: Sustained calcium entry through P2X nucleotide receptor channels in human airway epithelial cells. J Biol Chem 2003. 278:13398-13408.
23. Zsembery A, Fortenberry JA, Liang L, et al.: Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry. J Biol Chem 2004, 279:10720-10729. The combined approach of zinc and ATP offers a synergistic approach for sustained calcium entry and chloride secretion. Furthermore, zinc is a potent antioxidant and immunomodulatory micronutrient making it even more interesting as a potential therapy for cystic fibrosis.
24. Fischer H, Schwarzer C, Illek B: Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proc Natl Acad Sci USA 2004, 101:3691-3696. Airway surface liquid contains relatively high levels of vitamin C. This study demonstrates that vitamin C in addition to being an antioxidant has specific biological properties allowing it to activate CFTR. In addition to identifying an important biological function of vitamin C, this study invites further investigation into vitamin C as a therapy to stimulate CFTR activity once the protein has reached the apical membrane.
25. Zhang XM, Wang XT, Yue H, et al.: Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. J Biol Chem 2003, 278:51232-51242. Since it is possible to activate CFTR using such approaches as the antioxidant vitamin C, the use of organic solutes to coax CFTR to apical membranes is of particular interest.
26. Howard M, Fischer H, Roux J, et al.: Mammalian osmolytes and S-nitrosoglutathione promote Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J Biol Chem 2003, 278:35159-35167. The success of S-nitrosoglutathione in mobilizing ΔF508 CFTR to the apical membrane has therapeutic interest by itself. In addition, elucidation of the mechanism of action may lead to new insights for the use of redox molecules to influence the endoplasmic reticulum quality control machinery.
27. Ellgaard L, Helenius A: Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003, 4:181-191.
28. Egan ME, Glockner-Pagel J, Ambrose C, et al.: Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002, 8:485-492.
29. Egan ME, Pearson M, Weiner SA, et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304:600-602. Curcumin helps mobilize ΔF508 CFTR to plasma membranes by inhibiting calcium mobilization. Not only was this approach successful in vitro but mice homozygous for ΔF508 CFTR fed with a nontoxic amount of curcumin showed correction of nasal potential differences. Most interestingly, these mice fed with curcumin also demonstrated a marked improvement in the intestinal phenotype characteristic of cystic fibrosis disease.
30. a Song Y, Sonawane ND, Salinas D, et al.: Evidence against rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem, In press, 2004. Epub 2004 Jul 26. Using similar methods and reagents to those cited in reference 29, the authors were unable to see any evidence that curcumin helped mobilize ΔF508-CFTR to plasma membranes or helped correct nasal potential differences in 22 ΔF508 mice. The authors suggest that their work does not support further evaluation of curcumin as a therapy of CF.
31. Balasubramanyam M, Koteswari AA, Kumar RS, et al.: Curcumin-induced inhibition of cellular reactive oxygen species generation: Novel therapeutic implications. J Biosci 2003, 28:715-721. Because of the marked interest for curcuminin CF therapy, this study is of particular interest as it shows that curcumin also has potent antioxidant properties and likely inhibits protein kinase C. PKC is known to be involved in mucus secretion and other cell signaling events that are relevant to CF airway pathology.
32. Takeyama K, Dabbagh K, Jeong Shim J, et al.: Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000, 164:1546-1552.
33. Davies JR, Svitacheva N, Lannefors L, et al.: Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions. Biochem J 1999, 344:321-330.
34. Shao MX, Nakanaga T, Nadel JA: Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-{alpha} converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 2004, 287:L420-L427. The pathways that lead to oxidant-dependent mucin expression in the airways are becoming much more clearly defined. This study points to an important metalloproteinase that is activated by oxidants and may offer a novel therapeutic target.
35. Gopalakrishna R, Jaken S: Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000, 28:1349-1361.
36. Li Y, Martin LD, Spizz G, Adler KB: MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem 2001, 276:40982-40990.
37. Singer M, Martin LD, Vargaftig BB, et al.: A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma. Nat Med 2004, 10:193-196. MARCKS is the major PKC phosphorylation substrate. This study confirms the key importance of MARCKS in mucus hypersecretion. The MARCKS-related peptide used to block hypersecretion also offers a novel therapeutic avenue for the development of molecules that could control mucus hypersecretion induced by oxidative stress as seems to occur in CF.
38. Breuer W, Glickstein H, Kartner N, et al.: Protein kinase C mediates down-regulation of cystic fibrosis transmembrane conductance regulator levels in epithelial cells. J Biol Chem 1993, 268:13935-13939.
39. Khan TZ, Wagener JS, Bost T, et al.: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
40. Chen LF, Greene WC: Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5:392-401.
41. Asehnoune K, Strassheim D, Mitra S, et al.: Involvement of reactive oxygen species in toll-like receptor 4-dependent activation of NF-kappaB. J Immunol 2004, 172:2522-2529. NFκB activation is one of the central events occurring in the CF airway. Neutrophils are a rich source of NFκB and inflammatory cytokines. Oxidants were shown to be an essential early intermediate in the activation of NFκB by TLR4 bound to LPS. Antioxidants of clinical interest were found to prevent this LPS-dependent NFκB activation.
42. Konstan MW, Davis PB: Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002, 54:1409-1423.